History of hypersensitivity or allergy to any of the study drugs, drugs of similar chemical classes, ACE inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), or neprilysin inhibitors, as well as known or suspected contraindications to the study drugs.
Previous history of intolerance to recommended target doses of ACEIs or ARBs.
Known history of angioedema.
Requirement for treatment with both ACEIs and ARBs.
Current acute decompensated heart failure (exacerbation of chronic heart failure manifested by signs and symptoms that may require intravenous therapy).
Symptomatic hypotension.
Estimated glomerular filtration rate (eGFR) <30%.
Serum potassium >5.4 mmol/L.
Acute coronary syndrome, stroke, transient ischaemic attack, cardiac, carotid, or other major cardiovascular surgery, percutaneous coronary intervention, or carotid angioplasty within the 3 months.
Coronary or carotid artery disease likely to require surgical or percutaneous intervention within the 6 months.
Implantation of a cardiac resynchronization therapy (CRT) device within 3 months or intent to implant a CRT.
History of heart transplant or on a transplant list or with left ventricular (LV) assistance device.
History of severe pulmonary disease.
Diagnosis of peripartum- or chemotherapy-induced cardiomyopathy within the 12 months.
Documented untreated ventricular arrhythmia with syncopal episodes within the 3 months.
Symptomatic bradycardia or second- or third-degree atrioventricular block without a pacemaker.
Presence of haemodynamically significant mitral and/or aortic valve disease, except mitral regurgitation secondary to LV dilatation.
Presence of other haemodynamically significant obstructive lesions of the LV outflow tract, including aortic and subaortic stenosis.
Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of study drugs, including, but not limited to, any of the following: History of active inflammatory bowel disease during the 12 months. Active duodenal or gastric ulcers during the 3 months. Evidence of hepatic disease as determined by any one of the following: aspartate aminotransferase or alanine aminotransferase values exceeding 2x upper limit of normal, history of hepatic encephalopathy, history of oesophageal varices, or history of porto-caval shunt. Current treatment with cholestyramine or colestipol resins.
Presence of any other disease with a life expectancy of <5 years.

NCT03190304_exc_T1
Condition
hypersensitivity
NCT03190304_exc_T2
Condition
allergy
NCT03190304_exc_T3
Drug
study drugs
NCT03190304_exc_T5
Drug
ACE inhibitors (ACEIs)
NCT03190304_exc_T6
Drug
angiotensin II receptor blockers (ARBs)
NCT03190304_exc_T7
Drug
neprilysin inhibitors
NCT03190304_exc_T8
Condition
contraindications
NCT03190304_exc_T9
Mood
known
NCT03190304_exc_T10
Mood
suspected
NCT03190304_exc_T11
Scope
known or suspected
NCT03190304_exc_T12
Drug
study drugs
NCT03190304_exc_T13
Scope
study drugs, drugs of similar chemical classes, ACE inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), or neprilysin inhibitors
NCT03190304_exc_T14
Scope
hypersensitivity or allergy
NCT03190304_exc_T15
Drug
ACEIs
NCT03190304_exc_T16
Drug
ARBs
NCT03190304_exc_T17
Condition
intolerance
NCT03190304_exc_T18
Observation
history
NCT03190304_exc_T19
Temporal
Previous
NCT03190304_exc_T20
Scope
ACEIs or ARBs
NCT03190304_exc_T21
Condition
angioedema
NCT03190304_exc_T22
Drug
ACEIs
NCT03190304_exc_T23
Drug
ARBs
NCT03190304_exc_T24
Procedure
treatment
NCT03190304_exc_T25
Mood
Requirement for
NCT03190304_exc_T26
Scope
ACEIs and ARBs
NCT03190304_exc_T27
Observation
history
NCT03190304_exc_T28
Qualifier
acute
NCT03190304_exc_T29
Qualifier
decompensated
NCT03190304_exc_T30
Condition
heart failure
NCT03190304_exc_T31
Condition
exacerbation
NCT03190304_exc_T32
Condition
chronic heart failure
NCT03190304_exc_T33
Procedure
intravenous therapy
NCT03190304_exc_T34
Condition
signs
NCT03190304_exc_T35
Condition
symptoms
NCT03190304_exc_T36
Scope
signs and symptoms
NCT03190304_exc_T37
Scope
exacerbation of chronic heart failure
NCT03190304_exc_T38
Qualifier
Symptomatic
NCT03190304_exc_T39
Condition
hypotension
NCT03190304_exc_T40
Measurement
Estimated glomerular filtration rate (eGFR)
NCT03190304_exc_T41
Value
<30%
NCT03190304_exc_T42
Measurement
Serum potassium
NCT03190304_exc_T43
Value
>5.4 mmol/L
NCT03190304_exc_T44
Condition
Acute coronary syndrome
NCT03190304_exc_T45
Condition
stroke
NCT03190304_exc_T46
Condition
transient ischaemic attack
NCT03190304_exc_T47
Condition
cardiac
NCT03190304_exc_T48
Condition
carotid
NCT03190304_exc_T49
Procedure
major cardiovascular surgery
NCT03190304_exc_T50
Procedure
percutaneous coronary intervention
NCT03190304_exc_T51
Procedure
carotid angioplasty
NCT03190304_exc_T52
Temporal
within the 3 months
NCT03190304_exc_T53
Scope
major cardiovascular surgery, percutaneous coronary intervention, or carotid angioplasty
NCT03190304_exc_T54
Condition
carotid artery disease
NCT03190304_exc_T55
Condition
or carot sease likely t
NCT03190304_exc_T56
Procedure
or percu ion within t
NCT03190304_exc_T57
Mood
likely
NCT03190304_exc_T58
Procedure
percutaneous intervention
NCT03190304_exc_T59
Temporal
within the 6 months
NCT03190304_exc_T60
Scope
surgical or percutaneous intervention
NCT03190304_exc_T61
Scope
Coronary or carotid artery disease
NCT03190304_exc_T62
Device
cardiac resynchronization therapy (CRT) device
NCT03190304_exc_T63
Procedure
Implantation
NCT03190304_exc_T64
Temporal
within 3 months
NCT03190304_exc_T65
Mood
intent
NCT03190304_exc_T66
Procedure
implant
NCT03190304_exc_T67
Device
CRT
NCT03190304_exc_T68
Procedure
heart transplant
NCT03190304_exc_T69
Observation
History
NCT03190304_exc_T70
Observation
on a transplant list
NCT03190304_exc_T71
Device
left ventricular (LV) assistance device
NCT03190304_exc_T72
Observation
History
NCT03190304_exc_T73
Condition
severe pulmonary disease
NCT03190304_exc_T74
Condition
cardiomyopathy
NCT03190304_exc_T75
Procedure
chemotherapy
NCT03190304_exc_T76
Qualifier
chemotherapy-induced
NCT03190304_exc_T77
Condition
peripartum
NCT03190304_exc_T78
Qualifier
r chemother omyopat
NCT03190304_exc_T79
Scope
peripartum- or chemotherapy-induced
NCT03190304_exc_T80
Temporal
within the 12 months
NCT03190304_exc_T81
Condition
ventricular arrhythmia
NCT03190304_exc_T82
Qualifier
untreated
NCT03190304_exc_T83
Condition
syncopal episodes
NCT03190304_exc_T84
Temporal
within the 3 months
NCT03190304_exc_T85
Condition
bradycardia
NCT03190304_exc_T86
Condition
atrioventricular block
NCT03190304_exc_T87
Qualifier
third-degree
NCT03190304_exc_T88
Qualifier
d-degre tricul
NCT03190304_exc_T89
Negation
without
NCT03190304_exc_T90
Device
pacemaker
NCT03190304_exc_T91
Scope
second- or third-degree
NCT03190304_exc_T92
Qualifier
haemodynamically significant
NCT03190304_exc_T93
Condition
aortic valve disease
NCT03190304_exc_T94
Condition
rtic v xcept mitral
NCT03190304_exc_T95
Scope
mitral and/or aortic valve disease
NCT03190304_exc_T96
Condition
mitral regurgitation
NCT03190304_exc_T97
Qualifier
secondary to LV dilatation
NCT03190304_exc_T98
Condition
LV dilatation
NCT03190304_exc_T99
Negation
except
NCT03190304_exc_T100
Qualifier
haemodynamically significant
NCT03190304_exc_T101
Condition
obstructive lesions
NCT03190304_exc_T102
Qualifier
LV outflow tract
NCT03190304_exc_T103
Condition
subaortic stenosis
NCT03190304_exc_T104
Condition
tic st gical or
NCT03190304_exc_T105
Scope
haemodynamically significant obstructive lesions of the LV outflow tract
NCT03190304_exc_T106
Scope
aortic and subaortic stenosis
NCT03190304_exc_T107
Condition
l condit ght signi
NCT03190304_exc_T108
Condition
medical condition
NCT03190304_exc_T109
Condition
alter the absorption, distribution, metabolism, or excretion
NCT03190304_exc_T110
Drug
study drugs
NCT03190304_exc_T111
Condition
inflammatory bowel disease
NCT03190304_exc_T112
Scope
surgical or medical condition
NCT03190304_exc_T113
Scope
surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of study drugs
NCT03190304_exc_T114
Temporal
during the 12 months
NCT03190304_exc_T115
Qualifier
active
NCT03190304_exc_T116
Qualifier
Active
NCT03190304_exc_T117
Condition
c ulcers 3 mont
NCT03190304_exc_T118
Condition
gastric ulcers
NCT03190304_exc_T119
Scope
duodenal or gastric ulcers
NCT03190304_exc_T120
Temporal
during the 3 months
NCT03190304_exc_T121
Condition
hepatic disease
NCT03190304_exc_T122
Measurement
aspartate aminotransferase
NCT03190304_exc_T123
Measurement
alanine aminotransferase
NCT03190304_exc_T124
Value
exceeding 2x upper limit of normal
NCT03190304_exc_T125
Scope
aspartate aminotransferase or alanine aminotransferase
NCT03190304_exc_T126
Condition
hepatic encephalopathy
NCT03190304_exc_T127
Observation
history
NCT03190304_exc_T128
Condition
oesophageal varices
NCT03190304_exc_T129
Observation
history
NCT03190304_exc_T130
Observation
history
NCT03190304_exc_T131
Condition
porto-caval shunt
NCT03190304_exc_T132
Procedure
treatment
NCT03190304_exc_T133
Temporal
Current
NCT03190304_exc_T134
Drug
colestipol res f any
NCT03190304_exc_T135
Drug
colestipol resins
NCT03190304_exc_T136
Scope
cholestyramine or colestipol resins
NCT03190304_exc_T137
Mood
Evidence
NCT03190304_exc_T138
Scope
Evidence of hepatic disease
NCT03190304_exc_T139
Scope
aspartate aminotransferase or alanine aminotransferase values exceeding 2x upper limit of normal, history of hepatic encephalopathy, history of oesophageal varices, or history of porto-caval shunt. Current treatment with cholestyramine or colestipol resins
NCT03190304_exc_T140
Scope
active inflammatory bowel disease during the 12 months. Active duodenal or gastric ulcers during the 3 months. Evidence of hepatic disease as determined by any one of the following: aspartate aminotransferase or alanine aminotransferase values exceeding 2x upper limit of normal, history of hepatic encephalopathy, history of oesophageal varices, or history of porto-caval shunt. Current treatment with cholestyramine or colestipol resins
NCT03190304_exc_T141
Observation
life expectancy
NCT03190304_exc_T142
Value
<5 years
NCT03190304_exc_T143
Condition
disease
NCT03190304_exc_T144
Qualifier
any other